Nuveen Asset Management, LLC Denali Therapeutics Inc. Transaction History

Nuveen Asset Management, LLC

$334 Billion
Q2 2024

A detailed history of Nuveen Asset Management, LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 1,073,857 shares of DNLI stock, worth $31.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,073,857

Previous 508,196 111.31%

Holding current value

$31.6 Million

Previous $10.4 Million 139.11%

% of portfolio

0.01%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$14.96 - $23.22 $8.46 Million - $13.1 Million	565,661 Added 111.31%	1,073,857 $24.9 Million
Q1 2024 May 13, 2024	BUY	$15.83 - $23.35 $2.99 Million - $4.41 Million	188,759 Added 59.09%	508,196 $10.4 Million
Q4 2023 Feb 14, 2024	SELL	$16.2 - $23.18 $716,493 - $1.03 Million	-44,228 Reduced 12.16%	319,437 $6.86 Million
Q3 2023 Nov 14, 2023	SELL	$20.63 - $30.17 $36,948 - $54,034	-1,791 Reduced 0.49%	363,665 $7.5 Million
Q2 2023 Aug 14, 2023	BUY	$23.37 - $32.96 $112,643 - $158,867	4,820 Added 1.34%	365,456 $10.8 Million
Q1 2023 May 15, 2023	SELL	$21.91 - $32.67 $331,082 - $493,676	-15,111 Reduced 4.02%	360,636 $8.31 Million
Q4 2022 Feb 14, 2023	BUY	$26.28 - $33.92 $638,288 - $823,848	24,288 Added 6.91%	375,747 $10.4 Million
Q3 2022 Nov 14, 2022	SELL	$25.97 - $38.53 $225,913 - $335,172	-8,699 Reduced 2.42%	351,459 $10.8 Million
Q2 2022 Aug 15, 2022	SELL	$20.88 - $35.19 $210,282 - $354,398	-10,071 Reduced 2.72%	360,158 $10.6 Million
Q1 2022 May 16, 2022	SELL	$29.0 - $47.27 $197,635 - $322,145	-6,815 Reduced 1.81%	370,229 $12.3 Million
Q4 2021 Feb 14, 2022	BUY	$42.59 - $55.02 $509,631 - $658,369	11,966 Added 3.28%	377,044 $16.8 Million
Q3 2021 Nov 12, 2021	SELL	$48.48 - $78.23 $920,247 - $1.48 Million	-18,982 Reduced 4.94%	365,078 $19.3 Million
Q2 2021 Aug 16, 2021	BUY	$50.3 - $78.44 $5.35 Million - $8.35 Million	106,439 Added 38.34%	384,060 $30.1 Million
Q1 2021 May 17, 2021	SELL	$53.8 - $81.53 $766,165 - $1.16 Million	-14,241 Reduced 4.88%	277,621 $15.9 Million
Q4 2020 Feb 16, 2021	SELL	$36.89 - $93.56 $1.35 Million - $3.41 Million	-36,489 Reduced 11.11%	291,862 $24.4 Million
Q3 2020 Nov 16, 2020	SELL	$23.13 - $38.84 $30,716 - $51,579	-1,328 Reduced 0.4%	328,351 $11.8 Million
Q2 2020 Aug 14, 2020	BUY	$16.01 - $28.82 $740,318 - $1.33 Million	46,241 Added 16.31%	329,679 $7.97 Million
Q1 2020 May 14, 2020	BUY	$14.2 - $27.98 $1.46 Million - $2.88 Million	103,045 Added 57.12%	283,438 $4.96 Million
Q4 2019 Feb 14, 2020	BUY	$14.4 - $19.99 $16,747 - $23,248	1,163 Added 0.65%	180,393 $3.14 Million
Q3 2019 Nov 14, 2019	BUY	$15.32 - $21.92 $65,186 - $93,269	4,255 Added 2.43%	179,230 $2.75 Million
Q2 2019 Aug 15, 2019	BUY	$18.5 - $28.14 $3.24 Million - $4.92 Million	174,975 New	174,975 $3.63 Million

Others Institutions Holding DNLI

# of Institutions

214

Shares Held

121M

Call Options Held

127K

Put Options Held

38.3K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.95B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Denali Therapeutics Inc. Transaction History